Tumor neoantigens more accurately predict outcomes in melanoma patients treated with first-line anti-PD-1 or anti-CTLA-4 therapy compared to other biomarkers such as PD-L1 levels and mutational burden (50). The gene discussed is CTLA4; the disease is melanoma.